In patients with atrial fibrillation (AFib) and left ventricular systolic dysfunction (LVSD), catheter ablation was associated with substantial improvement in LVEF regardless of late gadolinium enhancement (LGE) status, while 12-month LVEF and normalization rates were lower in patients with LGE present, according to results from the CAMERA-MRI II trial published June 8 in JACC: Clinical Electrophysiology.
Lipid management remains a cornerstone of secondary prevention in atherosclerotic cardiovascular disease (ASCVD), with increasingly strong evidence supporting its central role across all vascular territories, including coronary, cerebrovascular, and peripheral arterial beds.
Supplementation with the vitamin K homologue menaquinone-7 (MK-7) significantly attenuated coronary artery calcification (CAC) compared with placebo in adults with symptomatic coronary artery disease (CAD), according to research published June 10 in JAMA Cardiology.
Administration of sodium bicarbonate made no significant difference in the sustained return of spontaneous circulation, compared with placebo, in patients who suffered an in-hospital cardiac arrest, according to research published June 11 in JAMA.
When compared with liberal oxygen therapy, conservative oxygen therapy did not improve rates of survival with favorable functional outcomes among unresponsive patients in the intensive care unit (ICU) receiving mechanical ventilation after cardiac arrest, according to results from the investigator-initiated, open-label LOGICAL trial published June 10 in NEJM.
The American Diabetes Association Applauds Louisiana Lawmakers for Advancing Diabetes-Related Amputation Prevention through House Resolution 267 vcramer Tue, 06/16/2026 - 12:54 Advocacy News The American Diabetes Association Applauds Louisiana Lawmakers for Advancing Diabetes-Related Amputation Prevention through House Resolution 267 Baton Rogue, LA June 16, 2026 The American Diabetes Association® (ADA) applauds the Louisiana House of Representatives for passing House Resolution 267 (HR 267), a measure establishing a comprehensive study focused on the prevention and reduction…
PHILADELPHIA, June 15, 2026 – The American College of Physicians (ACP) has issued a new living clinical guideline to help physicians choose medications with lifestyle modifications to manage overweight and obesity in adults. “ Pharmacologic Treatments with Lifestyle Modifications in Nonpregnant Adults with Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline from the American College of Physicians” is published in Annals of Internal Medicine . More than half (59%) of the world’s population has overweight or obesity, chronic conditions…
The ADA Acknowledges Continued Federal Funding for Diabetes Research and Prevention vcramer Fri, 06/12/2026 - 19:43 Official Statement The ADA Acknowledges Continued Federal Funding for Diabetes Research and Prevention Arlington, Va. June 15, 2026 The American Diabetes Association® (ADA) issued the following statement in response to the House Appropriations Committee’s passage of the Fiscal Year (FY) 2027 funding bill for the Department of Health and Human Services (HHS). This week, the House Appropriations Committee passed a FY 2027 funding measure that…
Patients who underwent mitral transcatheter edge-to-edge repair (M-TEER) with an optimal result were more likely to have improved hemodynamics and less likely to experience major adverse events, all-cause mortality, heart failure (HF) hospitalization or reintervention at one year...
The American Diabetes Association and The Leapfrog Group Recognize Hospitals Offering High-Quality Care for People Living with Diabetes mcarmody Thu, 06/11/2026 - 21:05 Press release The American Diabetes Association and The Leapfrog Group Recognize Hospitals Offering High-Quality Care for People Living with Diabetes ARLINGTON, Va. June 16, 2026 Today, the American Diabetes Association ® (ADA) and The Leapfrog Group announced the 2026 Recognized Leaders in Caring for People Living with Diabetes. Thirty-seven hospitals across 14 states earned the recognition this year, reflecting each…
Statement from the American Diabetes Association Regarding 2026 Scientific Sessions mcarmody Wed, 06/10/2026 - 16:55 Official Statement Statement from the American Diabetes Association Regarding 2026 Scientific Sessions ARLINGTON, Va. June 10, 2026 Today, Charles "Chuck" Henderson, chief executive officer of the American Diabetes Association ® (ADA) issued a statement and apology reflecting on events that occurred during the ADA’s 2026 Scientific Sessions in New Orleans. The ADA is commissioning a thorough independent review of the events that occurred, and we remain committed to…
Statement attributable to: Jan K. Carney, MD, MPH, MACP President, American College of Physicians WASHINGTON, June 9, 2026—The American College of Physicians (ACP) is deeply concerned about the Office of Management and Budget’s proposed changes to the rules governing federal grants. The proposed rules would direct “senior appointees” at federal agencies to take charge of awarding and terminating new and existing research grants and other federal awards. As an organization with a mission to promote evidence-based medicine, we know the value of independent review by clinical and scientific…
PHILADELPHIA, June 9, 2026— Former American College of Physicians (ACP) President, Sandra A. Fryhofer, MD, MACP, was elected the American Medical Association (AMA) President-Elect at the AMA House of Delegates Annual Meeting in Chicago earlier today. Dr. Fryhofer will be AMA President-Elect 2026 to 2027 and will assume the role of AMA President the following year. “Dr. Fryhofer has been a strong advocate for internal medicine, physicians, and our patients for years,” said Jan K. Carney, MD, MPH, president, ACP. “With her background in public health, her work in vaccine advocacy, and her…
Statement attributable to: Jan K. Carney, MD, MPH, MACP President, American College of Physicians WASHINGTON June 8, 2026— The American College of Physicians is relieved by a federal judge’s decision to immediately stop the $100,000 fee that the Trump administration had imposed on H1-B visa applications, starting on Sept. 21, 2025, calling its implementation unlawful. The sudden imposition of this dramatically increased visa fee has been very difficult for employers of noncitizen medical residents and other international medical graduates to meet. International medical graduates are…
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results mcarmody Mon, 06/08/2026 - 08:49 Press release Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results NEW ORLEANS, La. June 8, 2026 Findings highlight potential to expand oral GLP-1 RA treatment options for patients with type 2 diabetes and obesity Findings from two phase 2 studies demonstrated positive outcomes for elecoglipron, an investigational oral, once-daily, small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), in patients with type 2 diabetes…
The American Diabetes Association’s Statement Regarding Nonpartisanship mcarmody Sun, 06/07/2026 - 15:46 Official Statement The American Diabetes Association’s Statement Regarding Nonpartisanship ARLINGTON, Va. June 7, 2026 As many of you are now aware, an incident took place at the American Diabetes Association’s (ADA) Scientific Sessions. As a 501(c)(3) organization, the ADA has safeguards in place to ensure that it complies with all IRS regulations. This includes maintaining a strictly nonpartisan environment at all organizational events and functions while engaging across party…
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications mcarmody Sun, 06/07/2026 - 15:18 Press release Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications NEW ORLEANS, La. June 7, 2026 Embargoed until Sunday, June 7, 2026, at 4:30 p.m. CT Findings Demonstrate Potential for Amylin and GLP-1 Combinations as Next Generation of Weight Loss and Diabetes Treatment New international study findings demonstrated positive results of the first injectable glucagon-like peptide-1…
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes mcarmody Sun, 06/07/2026 - 13:28 Press release Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes NEW ORLEANS, La. June 7, 2026 Once-Monthly Injection Reduced Triglycerides and the Risk of Acute Pancreatitis; Bi-Weekly Injection Lowered “Bad” Cholesterol and Cardiovascular Events New data presented at the 2026 Scientific Sessions of the American Diabetes Association ® (ADA) demonstrate the benefits of using medications to address…
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health mcarmody Sun, 06/07/2026 - 06:28 Press release Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health NEW ORLEANS, La. June 7, 2026 Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in Adults New data highlight the potential benefits of survodutide, a once-weekly injectable therapy targeting both the glucagon and glucagon-like peptide-1 (GLP-1) receptors in individuals with obesity and metabolic dysfunction-associated…
The American Diabetes Association Announces Winners of the Innovation Challenge mcarmody Sat, 06/06/2026 - 18:52 Press release The American Diabetes Association Announces Winners of the Innovation Challenge NEW ORLEANS, La. June 6, 2026 Today, from the main stage at the organization’s 2026 Scientific Sessions, the American Diabetes Association ® (ADA) announced the winners of the 2026 Innovation Challenge competition. Each year, the Innovation Challenge seeks game-changing ideas from emerging companies that have the potential to transform diabetes care. “There is tremendous…
These findings highlight the potential importance of identifying abnormal anthropometric characteristics in clinical settings to better capture individuals at risk for obesity-related health complications.